Insider Buying: Auna (NYSE:AUNA) President Purchases 8,727 Shares of Stock

Auna S.A. (NYSE:AUNA) President Leon Jesus Zamora purchased 8,727 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average price of $4.24 per share, for a total transaction of $37,002.48. Following the completion of the transaction, the president owned 39,437 shares in the company, valued at $167,212.88. The trade was a 28.42% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Leon Jesus Zamora also recently made the following trade(s):

• On Wednesday, May 27th, Leon Jesus Zamora purchased 23,273 shares of Auna stock. The shares were acquired at an average price of $4.20 per share, for a total transaction of $97,746.60.

Auna Price Performance

NYSE AUNA traded up $0.04 during trading hours on Thursday, reaching $4.20. 333,444 shares of the company’s stock were exchanged, compared to its average volume of 352,403. The stock has a market cap of $310.47 million, a PE ratio of 16.14 and a beta of 1.03. The company has a current ratio of 1.09, a quick ratio of 1.00 and a debt-to-equity ratio of 1.76. The firm has a fifty day moving average of $5.25 and a 200-day moving average of $5.02. Auna S.A. has a one year low of $4.13 and a one year high of $6.85.

Auna (NYSE:AUNA) last announced its quarterly earnings data on Friday, May 15th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.14). The firm had revenue of $336.84 million during the quarter, compared to the consensus estimate of $320.54 million. Auna had a net margin of 1.53% and a return on equity of 16.25%. On average, equities research analysts predict that Auna S.A. will post 0.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Auna in a research report on Friday, March 27th. JPMorgan Chase & Co. decreased their price objective on Auna from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Tuesday. Wall Street Zen lowered Auna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Zacks Research lowered Auna from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.97.

Hedge Funds Weigh In On Auna

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in Auna by 255.9% during the 1st quarter. Bank of America Corp DE now owns 16,886 shares of the company’s stock worth $93,000 after purchasing an additional 12,142 shares in the last quarter. Lazard Asset Management LLC bought a new position in Auna during the 1st quarter worth about $557,000. Renaissance Technologies LLC increased its holdings in Auna by 487.7% during the 1st quarter. Renaissance Technologies LLC now owns 668,457 shares of the company’s stock worth $3,683,000 after purchasing an additional 554,707 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Auna during the 1st quarter worth about $316,000. Finally, Sanctuary Advisors LLC bought a new position in Auna during the 1st quarter worth about $71,000.

About Auna

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.